Personal information

Activities

Employment (1)

University of Southern California: Los Angeles, CA, US

1992-09-01 to present | Professor (Department of Clinical Pharmacy)
Employment
Source: Self-asserted source
Paul Beringer

Works (50 of 62)

Items per page:
Page 1 of 2

Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions between Elexacaftor/Tezacaftor/Ivacaftor and Tacrolimus in Lung Transplant Recipients

Pharmaceutics
2023-05 | Journal article | Author
Contributors: Eunjin Hong; Eugeniu Carmanov; Alan Shi; Peter S. Chung; Adupa P. Rao; Kevin Forrester; Paul Beringer
Source: check_circle
Multidisciplinary Digital Publishing Institute
grade
Preferred source (of 2)‎

Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications

Expert Opinion on Drug Metabolism & Toxicology
2023-05-31 | Journal article | Author
Part of ISSN: 1742-5255
Part of ISSN: 1744-7607
Contributors: Eunjin Hong; Alan Shi; Paul Beringer
Source: Self-asserted source
Paul Beringer
grade
Preferred source (of 2)‎

Safety of elexacaftor/tezacaftor/ivacaftor dose reduction: mechanistic exploration through physiologically-based pharmacokinetic modeling and a clinical case series.

Pharmacotherapy
2023-03 | Journal article
Contributors: Hong E; Li R; Shi A; Almond LM; Wang J; Khudari AZ; Haddad S; Sislyan S; Angelich M; Chung PS et al.
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

PBPK-led guidance for cystic fibrosis patients taking elexacaftor-tezacaftor-ivacaftor with nirmatrelvir-ritonavir for the treatment of COVID-19

medRxiv
2022 | Other
EID:

2-s2.0-85125166286

Contributors: Hong, E.; Almond, L.M.; Chung, P.S.; Rao, A.P.; Beringer, P.M.
Source: Self-asserted source
Paul Beringer via Scopus - Elsevier

Physiologically Based Pharmacokinetic Modeling To Guide Management of Drug Interactions between Elexacaftor-Tezacaftor-Ivacaftor and Antibiotics for the Treatment of Nontuberculous Mycobacteria.

Antimicrobial agents and chemotherapy
2022-10 | Journal article
Contributors: Hong E; Almond LM; Chung PS; Rao AP; Beringer PM
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19.

Clinical pharmacology and therapeutics
2022-04 | Journal article
Contributors: Hong E; Almond LM; Chung PS; Rao AP; Beringer PM
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Preclinical Pharmacokinetics and Safety of Intravenous RTD-1.

Antimicrobial agents and chemotherapy
2022-01 | Journal article
Contributors: Park AYJ; Tran DQ; Schaal JB; Wang M; Selsted ME; Beringer PM
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Erratum: Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer (Neuro Oncol (2021) 23:10 (1656-1667) DOI: 10.1093/neuonc/noab041)

Neuro-Oncology
2021 | Journal article
EID:

2-s2.0-85122546641

Part of ISSN: 15235866 15228517
Contributors: Wang, W.; He, H.; Marín-Ramos, N.I.; Zeng, S.; Swenson, S.D.; Cho, H.-Y.; Fu, J.; Beringer, P.M.; Neman, J.; Chen, L. et al.
Source: Self-asserted source
Paul Beringer via Scopus - Elsevier

Chemical Synthesis of a Potent Antimicrobial Peptide Murepavadin Using a Tandem Native Chemical Ligation/Desulfurization Reaction.

The Journal of organic chemistry
2021-10 | Journal article
Contributors: Chaudhuri D; Ganesan R; Vogelaar A; Dughbaj MA; Beringer PM; Camarero JA
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer.

Neuro-oncology
2021-10 | Journal article
Contributors: Wang W; He H; Marín-Ramos NI; Zeng S; Swenson SD; Cho HY; Fu J; Beringer PM; Neman J; Chen L et al.
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Anti-Inflammatory Effects of RTD-1 in a Murine Model of Chronic <i>Pseudomonas aeruginosa</i> Lung Infection: Inhibition of NF-κB, Inflammasome Gene Expression, and Pro-IL-1β Biosynthesis

Antibiotics
2021-08 | Journal article | Author
Contributors: Mansour A. Dughbaj; Jordanna G. Jayne; A Young J. Park; Timothy J. Bensman; Marquerita Algorri; Andre J. Ouellette; Michael Selsted; Paul Beringer
Source: check_circle
Multidisciplinary Digital Publishing Institute
grade
Preferred source (of 2)‎

Engineered Cyclotides with Potent Broad in Vitro and in Vivo Antimicrobial Activity.

Chemistry (Weinheim an der Bergstrasse, Germany)
2021-08 | Journal article
Contributors: Ganesan R; Dughbaj MA; Ramirez L; Beringer S; Aboye TL; Shekhtman A; Beringer PM; Camarero JA
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Rhesus Theta Defensin 1 Promotes Long Term Survival in Systemic Candidiasis by Host Directed Mechanisms.

Scientific reports
2019-11 | Journal article
Contributors: Basso V; Tran DQ; Schaal JB; Tran P; Eriguchi Y; Ngole D; Cabebe AE; Park AY; Beringer PM; Ouellette AJ et al.
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

The Potential for QT Interval Prolongation with Chronic Azithromycin Therapy in Adult Cystic Fibrosis Patients.

Pharmacotherapy
2019-05 | Journal article
Contributors: Avedissian SN; Rhodes NJ; Ng TMH; Rao AP; Beringer PM
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Pharmacokinetics of Tedizolid in Plasma and Sputum of Adults with Cystic Fibrosis.

Antimicrobial agents and chemotherapy
2018-08 | Journal article
Contributors: Park AYJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Rhesus θ-Defensin-1 Attenuates Endotoxin-induced Acute Lung Injury by Inhibiting Proinflammatory Cytokines and Neutrophil Recruitment.

American journal of respiratory cell and molecular biology
2018-03 | Journal article
Contributors: Jayne JG; Bensman TJ; Schaal JB; Park AYJ; Kimura E; Tran D; Selsted ME; Beringer PM
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Suppression and resolution of autoimmune arthritis by rhesus θ-defensin-1, an immunomodulatory macrocyclic peptide.

PloS one
2017-11 | Journal article
Contributors: Schaal JB; Tran DQ; Subramanian A; Patel R; Laragione T; Roberts KD; Trinh K; Tongaonkar P; Tran PA; Minond D et al.
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.

Antimicrobial agents and chemotherapy
2017-09 | Journal article
Contributors: Bensman TJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation.

Antimicrobial agents and chemotherapy
2017-07 | Journal article
Contributors: Bensman TJ; Jayne JG; Sun M; Kimura E; Meinert J; Wang JC; Schaal JB; Tran D; Rao AP; Akbari O et al.
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Rhesus θ-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of Pseudomonas aeruginosa.

The Journal of antimicrobial chemotherapy
2015-10 | Journal article
Contributors: Beringer PM; Bensman TJ; Ho H; Agnello M; Denovel N; Nguyen A; Wong-Beringer A; She R; Tran DQ; Moskowitz SM et al.
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models.

Journal of chemical information and modeling
2015-07 | Journal article
Contributors: Ha H; Debnath B; Odde S; Bensman T; Ho H; Beringer PM; Neamati N
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

A novel phenylcyclohex-1-enecarbothioamide derivative inhibits CXCL8-mediated chemotaxis through selective regulation of CXCR2-mediated signalling.

British journal of pharmacology
2014-03 | Journal article
Contributors: Ha H; Bensman T; Ho H; Beringer PM; Neamati N
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Cystic fibrosis

Koda-Kimble and Young's Applied Therapeutics: The Clinical Use of Drugs
2013 | Book chapter
EID:

2-s2.0-84971330697

Contributors: Beringer, P.M.; Condren, M.
Source: Self-asserted source
Paul Beringer via Scopus - Elsevier

Nebulizer choice affects the airway targeting of amphotericin B lipid complex aerosols

Journal of Pharmacy Technology
2013 | Journal article
EID:

2-s2.0-84890454688

Part of ISSN: 87551225 15494810
Contributors: Lambros, M.P.; Beringer, P.M.; Wong-Beringer, A.
Source: Self-asserted source
Paul Beringer via Scopus - Elsevier

Doxycycline exhibits anti-inflammatory activity in CF bronchial epithelial cells.

Pulmonary pharmacology & therapeutics
2012-07 | Journal article
Contributors: Bensman TJ; Nguyen AN; Rao AP; Beringer PM
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Acute care clinical pharmacy practice: unit- versus service-based models.

Pharmacotherapy
2012-02 | Journal article
Contributors: American College of Clinical Pharmacy; Haas CE; Eckel S; Arif S; Beringer PM; Blake EW; Lardieri AB; Lobo BL; Mercer JM; Moye P et al.
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Aminoglycoside antibiotics

Basic Clinical Pharmacokinetics: Fifth Edition
2011 | Book chapter
EID:

2-s2.0-84970003948

Contributors: Beringer, P.; Winter, M.E.
Source: Self-asserted source
Paul Beringer via Scopus - Elsevier

Pharmacokinetics of doxycycline in adults with cystic fibrosis.

Antimicrobial agents and chemotherapy
2011-10 | Journal article
Contributors: Beringer PM; Owens H; Nguyen A; Benitez D; Rao A; D'Argenio DZ
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients.

Antimicrobial agents and chemotherapy
2011-05 | Journal article
Contributors: Minejima E; Choi J; Beringer P; Lou M; Tse E; Wong-Beringer A
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy.

International journal of antimicrobial agents
2010-12 | Journal article
Contributors: Wong-Beringer A; Joo J; Tse E; Beringer P
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Estimation of glomerular filtration rate by using serum cystatin C and serum creatinine concentrations in patients with human immunodeficiency virus.

Pharmacotherapy
2010-10 | Journal article
Contributors: Beringer PM; Owens H; Nguyen A; Mordwinkin N; Louie S; Mak M; Sattler F
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Recommended education for pharmacists as competitive clinical scientists.

Pharmacotherapy
2009-02 | Journal article
Contributors: Dowling TC; Murphy JE; Kalus JS; Nkansah NT; Chappell JS; Wiederhold NP; Beringer P; Crews KR; Grabinski JL; Evens RP et al.
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

GFR estimates using cystatin C are superior to serum creatinine in adult patients with cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
2008-09 | Journal article
Contributors: Beringer PM; Hidayat L; Heed A; Zheng L; Owens H; Benitez D; Rao AP
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis.

Pharmacotherapy
2008-07 | Journal article
Contributors: Beringer PM; Kriengkauykiat J; Zhang X; Hidayat L; Liu S; Louie S; Synold T; Burckart GJ; Rao PA; Shapiro B et al.
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine.

Journal of clinical pharmacology
2008-05 | Journal article
Contributors: Liu S; Beringer PM; Hidayat L; Rao AP; Louie S; Burckart GJ; Shapiro B
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Pilot study of continuous infusion cefepime in adult patients with cystic fibrosis.

The Journal of antimicrobial chemotherapy
2006-03 | Journal article
Contributors: Han EE; Beringer PM; Falck P; Louie S; Rao P; Shapiro B; Gill M
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis.

Antimicrobial agents and chemotherapy
2005-12 | Journal article
Contributors: Beringer P; Huynh KM; Kriengkauykiat J; Bi L; Hoem N; Louie S; Han E; Nguyen T; Hsu D; Rao PA et al.
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Suitability of caspofungin for aerosol delivery: physicochemical profiling and nebulizer choice.

Chest
2005-11 | Journal article
Contributors: Wong-Beringer A; Lambros MP; Beringer PM; Johnson DL
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings.

Antimicrobial agents and chemotherapy
2005-09 | Journal article
Contributors: Beringer P; Nguyen M; Hoem N; Louie S; Gill M; Gurevitch M; Wong-Beringer A
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Transporters and their impact on drug disposition.

The Annals of pharmacotherapy
2005-05 | Journal article
Contributors: Beringer PM; Slaughter RL
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule.

Cancer chemotherapy and pharmacology
2005-04 | Journal article
Contributors: Garcia AA; Pujari M; Jeffers S; Iqbal S; Lenz HJ; Beringer P; Louie S
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

A Comparison of Phenytoin-loading Techniques in the Emergency Department

Academic Emergency Medicine
2004 | Journal article
EID:

2-s2.0-1442270080

Part of ISSN: 10696563
Contributors: Swadron, S.P.; Rudis, M.I.; Azimian, K.; Beringer, P.; Fort, D.; Orlinsky, M.
Source: Self-asserted source
Paul Beringer via Scopus - Elsevier

A comparison of phenytoin-loading techniques in the emergency department.

Academic emergency medicine : official journal of the Society for Academic Emergency Medicine
2004-03 | Journal article
Contributors: Swadron SP; Rudis MI; Azimian K; Beringer P; Fort D; Orlinsky M
Source: Self-asserted source
Paul Beringer via Europe PubMed Central

Pharmacokinetics of Ibuprofen in children with cystic fibrosis.

Clinical pharmacokinetics
2004-01 | Journal article
Contributors: Han EE; Beringer PM; Louie SG; Gill MA; Shapiro BJ
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Stability and antibacterial activity of cefepime during continuous infusion.

Antimicrobial agents and chemotherapy
2003-06 | Journal article
Contributors: Sprauten PF; Beringer PM; Louie SG; Synold TW; Gill MA
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Potential role of macrolide antibiotics in the management of cystic fibrosis lung disease.

Current opinion in pulmonary medicine
2002-11 | Journal article
Contributors: Nguyen T; Louie SG; Beringer PM; Gill MA
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis.

The Journal of antimicrobial chemotherapy
2002-10 | Journal article
Contributors: Aminimanizani A; Beringer PM; Kang J; Tsang L; Jelliffe RW; Shapiro BJ
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Development of population pharmacokinetic models and optimal sampling times for ibuprofen tablet and suspension formulations in children with cystic fibrosis.

Therapeutic drug monitoring
2002-04 | Journal article
Contributors: Beringer P; Aminimanizani A; Synold T; Scott C
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.

Antimicrobial agents and chemotherapy
2001-12 | Journal article
Contributors: Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎

The clinical use of colistin in patients with cystic fibrosis.

Current opinion in pulmonary medicine
2001-11 | Journal article
Contributors: Beringer P
Source: Self-asserted source
Paul Beringer via Europe PubMed Central
grade
Preferred source (of 2)‎
Items per page:
Page 1 of 2

Peer review (7 reviews for 3 publications/grants)

Review activity for Clinical therapeutics. (4)
Review activity for Pharmaceutics. (1)
Review activity for Respiratory medicine. (2)